<DOC>
	<DOCNO>NCT00583024</DOCNO>
	<brief_summary>This investigational study involve treatment Ad/PSA vaccine men prostate cancer present evidence hormone refractory metastatic disease .</brief_summary>
	<brief_title>Phase II Study Adenovirus/PSA Vaccine Men With Hormone - Refractory Prostate Cancer</brief_title>
	<detailed_description>Subjects trial eligible recent evidence hormone refractory disease ( D3 ) either ( ) positive bone scan positive CT scan ( obvious soft tissue metastasis lymph node &gt; 1 cm ) , PSA double time &gt; /= 12 month , total PSA &lt; 5 mg/ml , asymptomatic ; ( b ) negative bone scan PSA doubling time , asymptomatic , candidate chemotherapy . This virus vaccine gene prostate specific antigen ( PSA ) place common cold virus term adenovirus ( Ad ) produce Ad/PSA product . The purpose study determine whether vaccination Ad/PSA vaccine induce anti-PSA immunity result destruction remain prostate cancer cell . Subjects vaccinate three time , injection administer 30-day interval . Based upon early clinical trial , vaccine consider safe induce major side effect . The investigator hope vaccination PSA virus cause body produce immunity PSA immunity destroy cell produce PSA . Since cell leave body produce PSA cancer cell , investigator propose vaccination ensue anti-PSA immunity kill prostate cancer cell . Importantly , treatment cause major side effect would treatment anti-cancer drug .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Inclusion criterion : Men prostate cancer present evidence hormone refractory disease ( D3 ) . Men positive bone scan positive CT scan ( obvious soft tissue metastasis lymph node &gt; 1 cm ) , PSA double time &gt; /= 6 month , total PSA &lt; 10 ng/ml , asymptomatic OR men negative bone scan negative CT scan PSA doubling time asymptomatic . Scans must obtain within 6 week initiation treatment . Written informed consent . Age &gt; /= 18 year . Required laboratory value ( obtain within 2 week initiation treatment ) Serum creatinine &lt; /= 2.0 mg/dL Adequate hematologic function : granulocyte &gt; /= 1800 per mm3 , platelet &gt; /= 100,000 per mm3 , WBC &gt; /= 3700 , lymphocytes &gt; 590 . Adequate hepatocellular function : AST &lt; 3x upper limit normal total bilirubin &lt; 1.5 mg/dl ( unless bilirubin elevation consistent Gilbert 's syndrome ) . Castrate level testosterone &lt; /= 50 ng/ml . PSA use eligibility criterion must draw within 28 day prior injection number 1 drawn Day 1 use baseline value . Exclusion criterion : Active unresolved clinically significant infection . Parenteral antibiotic &lt; 7 day prior initiation treatment . Evidence prior current CNS metastasis . Specific image necessary absence sign symptom . Comorbid medical condition would result life expectancy ( participation ) less 1 year . Patients compromise immune system ; congenital , acquire , druginduced ( immunosuppressive agent ) exclude study . Use prednisone dose high 10 mg daily ( equipotent steroid dos ) 7 day within 3 month initiation treatment allow . Preexisting malignancy require treatment within past 5 year except basal squamous cell cancer skin . Prior participation vaccine study noninfectious disease . Prior chemotherapy , define prior cytotoxic chemotherapy prostate cancer ( cancer unless 5 year elapse ) . Examples cytotoxic chemotherapy mitoxantrone/prednisone taxanes . Drugs Casodex ketoconazole treatment must complete least 6 week prior initiation treatment . The inability understand language clinical protocol . Allergy religious objection pork product ; Gelfoam produce pork .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>vaccine</keyword>
	<keyword>immunotherapy</keyword>
</DOC>